Pharmaceuticals

Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions

Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a...

2024-04-18 21:00 804

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

GAITHERSBURG, Md., April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2024-04-18 20:00 629

Siriraj Hospital Shines Spotlight on TAVI Procedure as Alternative for High-Risk Patients Requiring Aortic Valve Replacement

BANGKOK, April 18, 2024 /PRNewswire/ -- Siriraj Hospital, a leading healthcare institution inThailand, stands at the forefront of aortic valve disease treatment with Transcatheter Aortic Valve Implantation (TAVI). The minimally invasive procedure significantly reduces surgical trauma and post-sur...

2024-04-18 15:01 989

Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"

MELBOURNE, Australia, April 18, 2024 /PRNewswire/ -- Australia's newest biotech incubatorJumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaitedMelbourne-based facility at an ...

2024-04-18 11:00 1070

Q1 2024 Revenue and Business Update

MELBOURNE, Australia, April 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance  The Company reports unaudi...

2024-04-17 15:05 1081

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN ASIA

— Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant — – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – — Indian Organizations Chennai Liver Foundation and FIND Receive the Grant t...

2024-04-17 11:22 1165

CSafe Elevates Cell and Gene Therapy Transport with Reusable Cryogenic Solution

MONROE, Ohio, April 16, 2024 /PRNewswire/ -- CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, proudly announces the launch of a new line of cryogenic multi-use dewars for the cell and gene therapy market. The progressive technolog...

2024-04-16 20:47 1265

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2024-04-16 20:00 1426

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dis...

2024-04-16 08:00 983

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

* FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging * Collaboration agreement announced for joint development and commercialisation with UCSF * PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Australia, April 1...

2024-04-16 06:42 861

【C.S】Cordyceps Sunshine has extended its market footprint in the world's largest traditional Chinese herbal medicine market with the introduction of their Cinnamomum product line.

TAIPEI, April 16, 2024 /PRNewswire/ -- Cordyceps Sunshine Group【C.S】Group, having recently achieved a successful U.S. IPO, hosted the '2024 China International Biomedical Innovation Development Conference and Chinese Rare Medicinal Herbs Cinnamomum Industry Transformation and Upgrade Conference' ...

2024-04-16 06:00 1055

GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA

– Gilead Awards US$4 Million Globally (Excluding the United States) Through the Gilead ALL4LIVER Grant – – World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee – – South Korea's Association of Liver Patients and Survivors and the Taiwan re...

2024-04-15 13:06 1070

Bloomage Demonstrates Global Quality Management Excellence through On-Site Audit by Japan's PMDA

TOKYO, April 15, 2024 /PRNewswire/ -- Bloomage recently successfully completed the on-site Good Manufacturing Practice (GMP) audit conducted byJapan's Pharmaceuticals and Medical Devices Agency (PMDA).  As the official regulatory agency for pharmaceuticals inJapan, the PMDA holds significant resp...

2024-04-15 08:30 948

Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease

STOCKHOLM, April 11, 2024 /PRNewswire/ -- IFPA is delighted to announce the 7th IFPA Conference set to take place fromJune 27th to June 29th, 2024, in the picturesque city ofStockholm, Sweden. This year's conference promises to be a pivotal event for experts and stakeholders in the field of psori...

2024-04-11 16:00 1248

Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan

HELSINKI, Finland, April 11, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform") today announced a strategic partnership whereby CBC Co., Ltd. ("CBC"), will utilize its extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform's cutting-edge nanomedici...

2024-04-11 15:38 1254

CSafe unveils cutting-edge innovations to meet cold chain customer needs

The company will launch three new technologies at the upcoming LogiPharma 2024 event MONROE, Ohio, April 10, 2024 /PRNewswire/ -- CSafe, a leading active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announces it is launching three new technol...

2024-04-10 22:50 1738

3Shape Charts Sustainable Course with Release of Comprehensive Sustainability Report 2023

Highlighted in the company's latest report, 3Shape plans to inspire sustainability awareness in the dental industry through its new 5-year sustainability plan. COPENHAGEN, Denmark, April 10, 2024 /PRNewswire/ -- 3Shape, the global innovator in digital dentistry, is proud to unveil its 2023 Susta...

2024-04-10 18:29 1186

ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research

TOKYO, April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been launching a continuous stream of innovative organoid-related products. Displaying their advancements at key global forums including the 2024 International Organoid Summit, Alzheimer's Research UK Conference 2024, and ...

2024-04-10 14:05 1461

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first p...

2024-04-10 11:41 1741

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-04-09 20:00 1158
12345 ... 181